Psychosis affects one's physical, psychological, social, and existential health. Mental health recovery often involves a ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Researchers have identified a potential diagnostic tool for schizophrenia by measuring brain cell activity between the ...

Data presented at Psych Congress 2024 showed improvements in social functioning and quality of life over an eight-week ...

Initially conceptualized by the celebrated British psychiatrist Julian Leff, a specialist in schizophrenia who died in 2021, the therapy's name is apparently a bit of a misnomer. "It’s called ...

Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...

Art therapy can help individuals express thoughts and feelings without relying solely on words, providing a valuable outlet ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a ...

The distress from voices heard by schizophrenia patients were lessened when treated using digital avatars, new study showed.

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

Researchers have developed a potential diagnostic tool for schizophrenia by observing how patients process conflicting information.